$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter

Wall Street brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post sales of $14.56 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The lowest sales estimate is $13.63 million and the highest is $15.73 million. Amicus Therapeutics posted sales of $2.83 million in the same quarter last year, which would indicate a positive year over year growth rate of 414.5%. The firm is expected to announce its next quarterly earnings results on Wednesday, March 7th.

On average, analysts expect that Amicus Therapeutics will report full year sales of $14.56 million for the current financial year, with estimates ranging from $32.90 million to $37.13 million. For the next fiscal year, analysts forecast that the company will post sales of $0.00 per share. Zacks’ sales averages are an average based on a survey of analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the prior year, the business posted ($0.33) EPS. The firm’s revenue for the quarter was up 419.0% on a year-over-year basis.

Several research analysts have recently issued reports on the stock. Leerink Swann raised their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a report on Thursday. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday. ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 17th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus price target of $19.06.

Shares of Amicus Therapeutics (NASDAQ FOLD) traded down $2.00 during trading on Monday, hitting $14.88. 5,667,333 shares of the stock traded hands, compared to its average volume of 3,259,764. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a 1 year low of $5.87 and a 1 year high of $17.40. The company has a market capitalization of $2,810.00, a PE ratio of -8.13 and a beta of 1.45.

In related news, CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $147,200.00. Following the sale, the chief financial officer now owns 105,121 shares in the company, valued at $1,547,381.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John F. Crowley sold 47,213 shares of Amicus Therapeutics stock in a transaction on Monday, December 4th. The shares were sold at an average price of $13.61, for a total transaction of $642,568.93. Following the completion of the sale, the chief executive officer now owns 375,214 shares in the company, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 250,390 shares of company stock worth $3,620,581. 3.40% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its position in Amicus Therapeutics by 3.4% during the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after buying an additional 591,925 shares during the period. Redmile Group LLC lifted its position in Amicus Therapeutics by 5.9% during the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after buying an additional 668,080 shares during the period. Jennison Associates LLC lifted its position in Amicus Therapeutics by 9.4% during the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after buying an additional 838,267 shares during the period. Vanguard Group Inc. lifted its position in Amicus Therapeutics by 5.0% during the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Amicus Therapeutics by 5.8% during the third quarter. Janus Henderson Group PLC now owns 7,434,314 shares of the biopharmaceutical company’s stock valued at $112,109,000 after buying an additional 407,304 shares during the period.

ILLEGAL ACTIVITY NOTICE: This story was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/08/14-56-million-in-sales-expected-for-amicus-therapeutics-inc-fold-this-quarter-2.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit